HC Wainwright Has Weak Estimate for ImmunityBio Q1 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – Investment analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of ImmunityBio in a research report issued on Monday, February 23rd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.07). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.60 EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.36 EPS.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter.

Several other research analysts also recently commented on IBRX. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday. Piper Sandler raised their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. BTIG Research boosted their target price on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Jefferies Financial Group increased their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.60.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $11.55 on Wednesday. The stock has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $3.24. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $12.28. The stock has a market capitalization of $11.38 billion, a PE ratio of -30.39 and a beta of 0.14.

Hedge Funds Weigh In On ImmunityBio

Hedge funds have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ grew its position in ImmunityBio by 347.7% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,028,921 shares during the period. Armistice Capital LLC acquired a new stake in shares of ImmunityBio in the 2nd quarter valued at $20,497,000. AlphaCore Capital LLC bought a new stake in shares of ImmunityBio in the 2nd quarter worth about $7,854,000. Geode Capital Management LLC increased its position in shares of ImmunityBio by 34.7% during the 2nd quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock worth $15,254,000 after purchasing an additional 1,487,849 shares in the last quarter. Finally, CWM LLC lifted its holdings in ImmunityBio by 849.2% during the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock valued at $129,000 after purchasing an additional 43,583 shares during the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ImmunityBio

In related news, Director Christobel Selecky sold 50,000 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the sale, the director directly owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 426,967 shares of company stock valued at $3,565,662 over the last ninety days. 69.48% of the stock is owned by insiders.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.